As such, we evaluated p-NFκB-p65 expression in a small subset of ER+/HER2- primary BC and bone metastases tissue (n = 4) and compared to PEDF expression levels previously determined in the same specimens from this patient cohort by our group [19], to determine if there is any association between PEDF and p-NFκB-p65 expression in human BC and bone metastases tissue (Figure 5). The gene discussed is ERBB2; the disease is breast cancer.